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Introduction
The Term biotechnology was first used in 1919 by hungarian engi-neer Karl ereky, but its official definition was established in 1992 at the Convention on Biological Diversity. This definition was subsequently 
ratified by 168 countries and accepted by the Food and Agriculture Organiza-
tion (FAO) and the World health Organization (WhO) as “any technological 
application that uses biological systems, living organisms, or derivatives thereof, 
to make or modify products and processes for specific use.” With this definition 
in mind, we conclude that biotechnology is one of the oldest practices of hu-
manity, since its use in beer brewing and bread making started in ancient egypt, 
between 4000-2000 BC; and the fun continues with the use of biotechnology 
for the production of cheese and wine.1 The expression used here, translational 
biotechnology, is paraphrased from that used in medicine, i.e., “from bench to 
bedside”, and aims to emphasize the use of biotechnology as a science linked to 
innovation, whose results are applicable to improve the living conditions of the 
population as well.
In daily academic life, biotechnology is a science deeply guided by the 
scientific method. Ideally, the results generated by biotechnology should be ul-
timately converted into commercial products, thus establishing a strong correla-
tion between this science and the concept of innovation; in the case of general 
industry, innovation means making a product available for consumption. Bio-
technology applies both to radical innovation, which involves original discover-
ies, and to incremental innovation, which can involve mere improvements to 
existing processes. For example, the development of a new molecule containing 
an active principle and that can serve as a basis for a new drug to be patented can 
ultimately become a radical innovation. So, the development of biotechnology 
projects is expected to yield results for the purpose of commercial ownership, 
thus contributing to improve the quality of life of individuals.2
The discovery of the DNA structure by Watson & Crick (1953) in march 
1953 demonstrated the mechanism for copying the genetic material responsible 
for the perpetuation of the species. This discovery enabled quickly advancing 
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the so-called “recombinant DNA techniques”, popularizing genetic manipula-
tion and making biotechnology a major agent for integrating various areas of 
knowledge  such as genetics, microbiology, biochemistry, physiology, cell biol-
ogy, pharmacology, and chemistry among others. An important fact in the pop-
ularization of biotechnology was the development by Kary B. mullis, in 1983, 
of the polymerase chain reaction (PCr) technique (Saiki et al. 1985). The PCr 
technique enables, in a very simple way, amplifying the genetic material in test 
tubes and has been applied to various fields of biotechnology.
In healthcare, biotechnology has been applied to the development of vac-
cines, gene and cell therapy, development and use of embryonic stem cells, as 
well as in the newly created synthetic cell, designed and developed in Craig C. 
Venter’s laboratory (Gibson et al., 2010). Furthermore, an important applica-
tion of biotechnology is the development of biopharmaceuticals, which may be 
understood as recombinant proteins intended for therapeutic use. The biophar-
maceuticals market already accounts for approximately 10 percent of the annual 
turnover of the pharmaceutical industry, which is around 800 billion dollars, 
with an expected annual growth of 3-6 percent. According to forecasts by ImS 
health, Brazil should contribute to this market between 5 and 15 billion dollars 
in annual sales of pharmaceutical products in 2013, with estimated revenue, for 
the Brazilian biopharmaceuticals market of 0.5-1.5 billion dollars.3
The use of biotechnology allowed the development by the company Ge-
nentech, in 1978, of the first biopharmaceutical produced using bacteria, name-
ly recombinant human insulin. in 1982, Genentech, in partnership with the 
eli Lilly Company, produced recombinant human insulin in an optimal way 
and received  approval for human use from the Food and Drug Administration 
(FDA).4 The production of insulin for human use manufactured from genetic 
engineering techniques has led to a significant reduction in problems associ-
ated with the impurity of the substance, which was originally purified from the 
pancreas of farm animals. The technique used in recombinant human insulin 
production is based on the insertion of human DNA into a host cell (E. coli, for 
example). The cells grow and reproduce normally, and thanks to the DNA code 
inserted into the host, produce their own insulin for human therapy. It should 
be noted that biotechnology is a pragmatic science, which today benefits more 
than 250 million patients who use biopharmaceuticals for the treatment of heart 
attacks, multiple sclerosis, breast cancer, cystic fibrosis, leukemia and diseases of 
genetic origin. Biotechnology has had a positive impact on the production of 
safe and effective vaccines for infectious diseases.
Currently, more than 350 drugs produced using biotechnology are in the 
process of being approved for the treatment of over 150 diseases, among which 
are cancer, infectious diseases and autoimmune disorders.5 The most important 
biopharmaceuticals at present are:
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•	 Factors such as blood Factor VIII and IX, used as clotting factor for 
hemophilia A and B.
•	 Thromboembolic activators for tissue plasminogen: used for condi-
tions associated with thrombosis and embolism.
•	 hormones, such as insulin (used for diabetes), growth hormones and 
gonadotropins.
•	 hematopoietic growth factors such as erythropoietin, which are fac-
tors related to the production of red blood cells used in the treatment 
of anemia caused by chronic renal failure or chemotherapy for cancer.
•	 Interferons-α,-β,-γ, which are natural proteins produced by immune 
cells in response to threat agents such as viruses, bacteria, parasites and 
tumors. Used to treat conditions such as multiple sclerosis, systemic 
cancer, hepatitis C, and leukemia.
•	 Interleukin-based products, which are used to treat Crohn’s disease 
and ulcerative colitis.
•	 Vaccines: for the prevention of various diseases.
•	 monoclonal antibodies, which are antibodies produced by a specific 
type of immune cells, all from a single mother cell (monoclonal). Used 
to treat a wide variety of diseases.
•	 Other products, such as therapeutic enzymes and tumor necrosis fac-
tor are used for autoimmune diseases such as rheumatoid arthritis, 
Crohn’s disease and many others.
Thus, we see that biotechnology is present in everyday life and provides 
options for the recombinant production of blood- or tissue-derived proteins, 
ensuring the safe and effective production of drugs, with no negative conse-
quences for the environment. most of the biopharmaceuticals described above 
and commercialized worldwide currently have a biogeneric substitute under 
development, because their patents are in the process of expiring. As a result, 
the development and production of generic biopharmaceuticals is currently an 
excellent opportunity both for academic laboratories with expertise in the pro-
duction of recombinant protein wishing to enter the field of innovation, and 
national biotechnology companies intending to expand their line of products 
and services.
Development of biotechnology
The following is a chronological description of the development of bio-
technology:
•	4000-2000 BC: “Biotechnology” was first used in egypt for the production of 
bread and beer, using the technique of fermentation by yeasts.
•	1322: horses of a superior breed were artificially inseminated by an Arab leader.
•	1761: Plants of different species were crossed by German naturalist Joseph 
Gottlieb Koelreuter.
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•	1859: The distinguished British scientist Charles Darwin published his theory 
of evolution by natural selection. The concept of selecting and destroying the 
weaker offspring had great influence among livestock breeders in the mid-
nineteenth century, although genetics was not yet a recognized science.
•	1865: Genetics emerged under the mentorship of Austrian scientist Gregor 
mendel. Through his experiments with peas, mendel found that characteris-
tics are hereditary, passed from father to son; he also discovered the patterns 
of heredity.
•	1870: Using Darwin’s theory, plant breeders began to cross different cotton 
species and ultimately succeeded in developing a superior variety of the plant.
•	1876: Louis Pasteur proved that fermentation was caused by the action of tiny 
living beings, i.e., microorganisms, thus disproving the then existing theory 
that fermentation would be a purely chemical process.
•	1879: Scientist Alexander Fleming discovered chromatin, a structure resem-
bling a wand inside the nucleus of cells, which was later called “chromosome.”
•	1897: eduard Buchner proved possible to convert sugar into alcohol, using 
macerated yeast cells, i.e., in the absence of living organisms.
•	1900: Fruit flies, Drosophila melanogaster, were used in early studies of genes.
•	1906: The term “genetics” was coined.
•	1919: The word biotechnology was used by hungarian engineer Karl ereky.
•	1941: The term genetic engineering was used for the first time.
•	1942: Penicillin began to be produced as a drug and used as an antibiotic in 
humans.
•	1944: DNA was found to be the structure responsible for the transmission of 
genetic information.
•	1953: Scientists James Watson and Francis Crick resolved the structure of 
DNA. Their article was published in the journal Nature and marked the era of 
contemporary genetics.
•	1956: The fermentation process was optimized; Arthur Kornberg discovered 
the DNA polymerase I enzyme that catalyzes DNA synthesis in bacteria, lead-
ing to the understanding of how DNA is replicated.
•	1958: DNA was first produced in a test tube.
•	1969: An enzyme was synthesized in vitro for the first time ever.
•	1970: restriction enzymes (specific nucleases) were identified, paving the way 
for molecular cloning of genes.
•	1972: The composition of human DNA was found to be 99 percent similar to 
that of chimpanzees and gorillas.
•	1975: The first monoclonal antibodies were produced.
•	1982: FDA approved the first human insulin produced by genetically modified 
bacteria.
•	1983: Kary B. mullis developed the polymerase chain reaction (PCr) tech-
nique.
•	1984: The first cloning and sequencing of the entire hIV virus was announced.
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•	1986: The first recombinant vaccine against hepatitis B for humans was pro-
duced; the first anticancer drug was produced through biotechnology.
•	1990: The human Genome Project was launched. In the United States, a 
four-year old girl suffering from  immune system disorder became the first hu-
man recipient of gene therapy .
•	1994: The first breast cancer gene was discovered.
•	1995: Gene therapy joins the fight against cancer. The first sequenced genome 
of a living organism other than viruses is completed for the Haemophilus in-
fluenzae bacterium.
•	1996: Scottish scientists cloned identical copies of a sheep from embryos.
•	1997: Dolly the sheep, the first animal cloned from an adult cell, was born.
•	1998: human embryonic stem cells were discovered. The first complete ge-
nome of an animal, nematode C. elegans, was sequenced.
•	1999: The concept of interactome and the idea that proteins rarely perform 
their functions individually emerged.
•	2003: Dolly the sheep was submitted to euthanasia after developing lung can-
cer; China approved the first regulation for a gene therapy product.
•	2004: The first pet was cloned: a cat. The genome of mice used in laboratory 
research was sequenced.
•	2005: The FDA approved the first drug for a specific ethnic group: a drug 
for heart problem unique to people of African descent. The dog genome was 
published.
•	2010: Craig C. Venter published an article in the Science journal describing for 
the first time the development of a synthetic cell whose initial DNA was totally 
synthesized in laboratory under human control.
Source: Adapted from http://www.shire.com.br/tecnologia/biotecnologia.
The use of biotechnology in the academic discovery of novel bio-
active molecules
The study of small proteins called peptides that act on the nervous system 
has its origin in the 1940s-1950s, with the discovery of the peptide bradyki-
nin, published in 1949 by Professor mauricio rocha e Silva et al. (1949), at 
the School  of medicine of ribeirão Preto, and backed by more than eighteen 
thousand internationally recognized manuscripts. Bioactive peptides found in 
mammals which, like bradykinin play the most diverse physiological functions, 
currently total more than a hundred. What the peptides have in common is a 
protein structure encoded from a specific nucleotide sequence stored in the 
DNA. This peptide protein structure is initially produced as a protein, which 
needs to be hydrolyzed into very specific amino acids by enzymes called prote-
ases. After the release of their protein precursor, peptides gain biological activity 
and signal, usually in conjunction with other small non-protein molecules, cells 
and tissues that perform many different functions. Therefore, we now know that 
peptides play crucial functions in animal cells and organs, whether unicellular or 
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multicellular. It is common for the same cell or tissue to produce several pep-
tides simultaneously and use them to properly perform its functions. Like their 
protein precursors, peptides also need to be constantly degraded and recycled 
into amino acids, thus enabling a constant process of cell renewal. The enzymes 
that perform this peptide hydrolyzing function are termed peptidases, due to 
their ability to hydrolyze peptide bonds.
Peptidases, along with proteases, are proteins conserved throughout the 
evolution of species, accounting for approximately 2 percent of the genes en-
coded by the human genome, reiterating the biological importance of peptides 
and peptidases. A class of peptidases conserved throughout evolution and ex-
pressed ubiquitously in cells and tissues of mammals, including humans, are oli-
gopeptidases. These oligopeptidases, which were also discovered at the School 
of medicine of ribeirão Preto by Professor Antonio Carlos martins de Camargo 
et al. (1969) are scientifically interesting enzymes for many reasons, among 
them their unique structural conformation that allows entry of only small pep-
tides in their hydrolytic site. molecular cloning - i.e., the identification of the 
encoding DNA sequence - of the first mammalian oligopeptidase - was made in 
the early 1990s by the group of professors James L. roberts and marc J. Glucks-
man, from the mount Sinai School of medicine (New York), and spurred the 
development of knowledge in this area. Particularly, molecular cloning has en-
abled using bacterial expression systems for the production of an enzyme called 
thimet oligopeptidase (TOP or eP24.15) in previously unthinkable quantities 
and purity (cf. rioli et al. 1998). The advantages of using biotechnology to 
produce in microorganisms proteins that are normally found in vital organs of 
mammalians, such as the brain, the kidneys and the heart, include the quantity 
and purity of the material obtained. For example, at the end of the process and 
months of work, micrograms of purified material were obtained by the chro-
matographic method originally used to obtain this enzyme from kilograms of 
biological material (usually rabbit, rat or bovine brain). Biotechnology currently 
enables obtaining grams of this protein in just five days’ work, using a system 
of expression of recombinant proteins in bacteria. This has enabled determin-
ing the crystallographic structure of eP24.15, which is a determining factor for 
understanding its restriction to hydrolyzing small peptides.
Thus, mastering the process of producing recombinant oligopeptidase 
such as eP24.15 has enabled using it for the structural characterization of its 
biochemical specificities, as well as for the production of highly specific antibod-
ies. In addition to these important aspects, protein expression in biotechnology 
enables performing rational structural changes in the amino acid sequence of 
the expressed protein. This manipulation of the genetic code (genetic engineer-
ing) can be used for several purposes, among them to rationally manipulate 
enzyme activity. It is therefore possible to produce enzymes, for example, that 
are stable at high temperature or catalytically inactive.
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Given these biotechnological possibilities, the use of a catalytically inac-
tive form of oligopeptidase eP24.15 has allowed using it for the discovery of 
a novel family of molecules, i.e., intracellular peptides. In her doctoral thesis, 
defended in 2003 at the Federal University of São Paulo in the area of mo-
lecular Biology Concentration, biologist Vanessa rioli first described the use 
of inactive oligopeptidases for the isolation of new peptide sequences (rioli et 
al. 2003). Among the original peptides identified was a fragment of the alpha 
chain of the nine amino acid hemoglobin which, due to its hypotensive activity 
was named hemopressin. It is important to point out that the identification of 
hemopressin, and subsequently of a hundred several other intracellular peptides, 
was only made possible by the use of mass spectrometry, drawing attention to 
the multidisciplinary nature of biotechnology which, combined with other con-
temporary sciences enables significant advances in scientific knowledge. With 
the discovery of a new bioactive peptide sequence like hemopressin, it was pos-
sible to carry out further investigations involving its pharmacological function 
and molecular mechanism of action. With additional pharmacological tests, a 
group of researchers led by physicians Camila S. Dale (Syrian-Lebanese hos-
pital), Andrea S. heimann (Proteimax Biotechnology Ltd.) And Lakshmi A. 
Devi (mount Sinai School of medicine) found that, in addition to hypotensive 
action, hemopressin also has an analgesic activity that involves the antagonism 
of cannabinoid receptors (heimann, 2007). The discovery that the molecular 
mechanism of action of hemopressin involves the antagonism of cannabinoid 
receptors had worldwide repercussions. more recently, the demonstration that 
hemopressin acting as an inverse agonist of cannabinoid receptors inhibits food 
intake in laboratory animals - an effect opposite to that of cannabinoid agonists 
present in plants such as Cannabis sativa - has further increased the interest of 
both  the scientific community and society in this peptide.
The extent to which hemopressin - a peptide discovered using biotechnol-
ogy in the course of a thesis guided by a hypothesis and popularized by scientific 
publications demonstrating its potential therapeutic relevance - will become an 
innovation remains a question to be answered. Both individuals and companies 
have endeavored  in this regard, considering what has been learned from the 
experiences of previous research groups.
The use of biotechnology                                                                                                                                    
in changing scientific paradigms
The use of biotechnology for the production of inactive oligopeptidases 
allowed the development of a method, patented by the University of São Paulo 
and the research Support Foundation of the State of São Paulo (FAPeSP), 
which led to the discovery of new peptides (Cunha, 2008). As a result, what was 
observed was the presence of large numbers of peptides derived from proteins 
present, particularly, in the cytoplasm, nuclei and mitochondria. Intracellular 
protein-derived peptides had hitherto been described only separately and spo-
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radically, and in general were seen only as inactive intermediates in the produc-
tion of amino acids for the synthesis of new proteins, as well as an integral part 
of the autoimmune recognition system. however, signals for post-translational 
modifications, especially phosphorylation, which are often found in proteins 
that participate in the regulation of intracellular signaling cascades, particularly 
during transduction of the signal mediated by plasma membrane receptors, were 
found in the peptides identified with the use of inactive oligopeptidases. The 
doctoral thesis of pharmacist Fernanda marques da Cunha, defended at the 
Federal University of São Paulo, and of biomedical scientist Denise Aparecida 
Berti, defended at the University of São Paulo, investigated the possible exis-
tence and physiopharmacological relevance of what had been envisioned as a 
new family of intracellular signaling molecules. Thus, it was demonstrated for 
the first time ever that peptides naturally found intracellularly are capable of in-
terfering in cell signaling mediated by two important pharmacological agonists, 
namely angiotensin II and isoproterenol. Furthermore, it was demonstrated 
that manipulation of the intracellular activity of oligopeptidase eP24.15, which 
alters per se the intracellular peptide composition was sufficient to alter the gene 
transcription resulting from the cell signaling initiated by the aforementioned 
pharmacological agonists (cf. Cunha, 2008; Berti et al. 2009).
A specific physiological role of intracellular peptides seems to be that of 
regulating glucose uptake by adipose tissue. As a result of a hypercaloric diet 
(cafeteria diet), the composition of specific intracellular peptides changed in 
adipose tissue of mice that developed obesity and insulin resistance. Important 
to reaffirm the initial concept of translational biotechnology, the reintroduction 
of these intracellular peptides into fat cells was able to improve glucose uptake 
in insulin resistant cells. These recent studies, although still in progress, suggest 
an additional physiological role for intracellular peptides in insulin signaling in 
adipose tissue (Berti, n.d.).
Subsequent studies led by Professor Lloyd D. Fricker, from the Albert 
einstein College of medicine (New York) resulted in the systematic identifica-
tion of a large number of intracellular peptides in tissues such as brain, blood 
vessels and heart (see Gelman & Fricker, 2010). Additionally, studies conducted 
by biomedical scientist Leandro mantovani Castro, from the University of São 
Paulo, demonstrated that intracellular peptides described in mammalian tissues 
are not part of the autoimmune recognition system (Castro et al., 2010). These 
systematic studies demonstrated definitively the existence of a family of intracel-
lular peptides that can be found in many animals and their respective tissues. The 
existence of a similar composition of intracellular peptides in various cell types 
has also been demonstrated. recent studies also show significant changes in the 
composition of specific intracellular peptides, in animal models, of neurodegen-
erative diseases, as well as after the induction of cerebral ischemia. Therefore, it 
is possible to suggest that intracellular peptides play different physiopathological 
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functions in mammals. Thus, these studies developed within the process of aca-
demic science based on hypothesis and using biotechnology among other sci-
ences, change the paradigm that peptides formed during intracellular proteolysis 
are rapidly converted into amino acids for protein synthesis. Additional studies 
may be conducted to investigate the possible occurrence of changes in the intra-
cellular content of peptides in human diseases (cf. Fricker & Sweedler, 2010).
The new proposal of intracellular 
peptides acting in health and disease
An event organized in 2009 by rao rapaka, director of the National Insti-
tute of Drug Abuse (NIDA) / National Institute of health (NIh) discussed the 
prospects and future actions to discover the “hidden peptidome” (Fishing for the 
hidden Peptidome in health and Disease; USA, 2009). Proteome and peptidome 
are defined respectively as the set of proteins and peptides present in a tissue or bio-
logical sample. The suggested mechanism for the action of peptides intracellularly 
involves an internal operation in the cellular environment (Ferro et al., 2004), and 
another in the extracellular environment (Gomes, 2010), where they can be secret-
ed. Intracellularly, it is suggested that peptides are modulators of protein interaction 
networks, which are physiologically responsible for maintaining various cellular pro-
cesses. These protein interaction networks are also correlated with disease and may 
be used as prognostic methods, as they are altered, for example, in cancer. The first 
experimental evidence in investigating the role of intracellular peptides in protein 
interaction comes from the study of biologist Lilian Cristina russo Vieira. Using 
surface plasmon resonance, Dr. Lilian demonstrated that the interaction of specific 
proteins with those present in the cytosol of neuronal tissue is altered by the addition 
of specific intracellular peptides. Some of these peptides are able to increase - while 
others reduce - protein-protein interactions. To act in the extracellular environment, 
it is suggested that these peptides are secreted from cytosol by an unconventional 
secretory pathway. examples of known peptides derived from cytosolic proteins and 
that are secreted include hemorphins, which are peptide fragments derived from 
the beta chain of hemoglobin that act as opioid receptor agonists. however, to 
date there are no studies on the possible secretion of hemopressin or its precursors, 
such as rVD- and Vd-hemopressin or on other intracellular peptides resulting from 
the studies discussed herein. however, it is important to mention that recent stud-
ies have shown, in a very elegant way, hemoglobin expression in neuronal cells. In 
neurons it is suggested that hemoglobin functions as an antioxidant protein. Thus, 
both the protein precursor (hemoglobin alpha chain) and the hemopressin receptor 
(CB1 cannabinoid receptor) can be found in neurons of the central nervous system. 
As a result, we observe that our understanding of cell biology is far from being suf-
ficient, and that constant research in the most different areas of knowledge, such 
as biotechnology, mass spectrometry, cell biology, pharmacology, physiology, and 
pathology, among others, is essential for anyone planning to improve the quality of 
life of the population.
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Final considerations
In this paper we have sought to report the use of the knowledge acquired 
in the academic setting to establish correlations between a pragmatic science 
like biotechnology and hypothesis-oriented academic science. Note that are 
not necessarily disadvantages when these two sciences intertwine; instead, the 
primary result is the advancement of knowledge. The advances made over as 
little as eleven years, and that led to the identification of intracellular peptides 
as a new family of biologically active molecules, were only possible with the 
use of biotechnology and recombinant DNA techniques in conjunction with 
the introduction of mass spectrometry and classical concepts of pharmacology, 
physiology, biochemistry and cell biology. With the incorporation of new sci-
ences such as mass spectrometry applied to macromolecules and surface plas-
mon resonance, the time period required for fundamental discoveries has been 
significantly reduced. The ongoing work of researchers, generation after gen-
eration, is invaluable and contributes to the development of research lines that 
incorporate new findings and are improved as knowledge advances. The recent 
history of the discovery of hemopressin and intracellular peptides is an example 
in this regard.
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Notes
1 See <http://www.roche.com.br/fmfiles/re7193008/pdf/medicamentosbiologi-
cos1. pdf>; Fardelone & Branchi  (2006); Vieira & Ohayon (s. d.);  Global... (2008); 
Como estimular  a inovação  tecnológica (2010).
2 See <http://www.roche.com.br/fmfiles/re7193008/pdf/medicamentosbiologi-
cos1. pdf>; Fardelone & Branchi  (2006); Vieira & Ohayon (s. d.);  Global... (2008); 
Como estimular  a inovação  tecnológica (2010).
3 See. <http://www.roche.com.br/fmfiles/re7193008/pdf/medicamentosbiologi-
cos1. pdf>; Fardelone & Branchi  (2006); Vieira & Ohayon (s. d.);  Global... (2008); 
Como estimular  a inovação  tecnológica (2010).
4 See  <http://www.shire.com.br/tecnologia/biotecnologia>.
5 See <http://www.roche.com.br/fmfiles/re7193008/pdf/medicamentosbiologi-
cos1. pdf>; Fardelone & Branchi  (2006); Vieira & Ohayon (s. d.);  Global... (2008); 
Como estimular  a inovação  tecnológica (2010).
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abStract  – Biotechnology has been used since ancient egypt for the production of 
bread and beer.  In the modern world, biotechnology has been used in several ways, 
including for the treatment of diseases. In academia, biotechnology has allowed a rapid 
advance of knowledge. In this article, we provide a brief summary of what biotechnolo-
gy is and its relation to the process of innovation and production of biopharmaceuticals. 
In academia, biotechnology has contributed decisively to the discovery of new bioactive 
molecules, such as in hemopressin and several other intracellular peptides.
KEywordS:  Translational  medicine,  Interactome, molecular  biology,  Cell  signaling, 
mass spectrometry.
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